Kymera Therapeutics (KYMR) EBIAT: 2019-2025
Historic EBIAT for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -$82.2 million.
- Kymera Therapeutics' EBIAT fell 31.51% to -$82.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.1 million, marking a year-over-year decrease of 76.22%. This contributed to the annual value of -$223.9 million for FY2024, which is 52.32% down from last year.
- As of Q3 2025, Kymera Therapeutics' EBIAT stood at -$82.2 million, which was down 7.26% from -$76.6 million recorded in Q2 2025.
- Kymera Therapeutics' EBIAT's 5-year high stood at -$13.1 million during Q1 2021, with a 5-year trough of -$82.2 million in Q3 2025.
- In the last 3 years, Kymera Therapeutics' EBIAT had a median value of -$52.9 million in 2023 and averaged -$54.1 million.
- In the last 5 years, Kymera Therapeutics' EBIAT spiked by 58.79% in 2023 and then plummeted by 392.43% in 2024.
- Over the past 5 years, Kymera Therapeutics' EBIAT (Quarterly) stood at -$33.9 million in 2021, then dropped by 2.85% to -$34.9 million in 2022, then skyrocketed by 58.79% to -$14.4 million in 2023, then crashed by 392.43% to -$70.8 million in 2024, then crashed by 31.51% to -$82.2 million in 2025.
- Its EBIAT was -$82.2 million in Q3 2025, compared to -$76.6 million in Q2 2025 and -$65.6 million in Q1 2025.